0. Advocacy Webpage Graphics-Narrow -Standardize It 

There are many misconceptions about the disease of addiction, and a culture change is needed in this country to drive patients to the treatment options that have proven to be effective at reducing overdose deaths and supporting patients in remission and recovery. ASAM advocates for the use of nationally recognized guidelines and standards for the treatment of addiction and the dissemination of competency-based addiction education for all healthcare professionals.

The ASAM Criteria®, the most widely used and comprehensive set of guidelines for placement, continued stay and transfer/discharge of patients with addiction and co-occurring conditions, is a fundamental tool for the standardization of addiction medicine.

ASAM Level of Care Cert final


Transforming the Delivery of Substance Use Disorder Treatment in States

This slide presentation describes ASAM tools and resources that can help states transform the delivery of substance use disorder treatment.


Featured Public Policy Statements

0. doctor patient

Regulation of Office-Based Opioid Treatment

OBOT promotes the treatment of addiction in the primary care setting, but ASAM understands that the use of controlled substances to treat addiction introduces the possibility of misuse and diversion of the very medications used for treatment.
2. medical-recordscrop

Prescription Drug Monitoring Programs (PDMPs)

Find out more about PDMPs and ASAM's recommendations on how they should be regulated.


Joint Public Correctional Policy Statement on the Treatment of Opioid Use Disorders for Justice Involved Individuals

Learn more about how ASAM and the American Correctional Association (ACA) are supporting the use of evidence-based practices for the treatment of opioid use disorders in correctional settings.

"By implementing a quality-driven national addiction treatment infrastructure, we can empower patients and their families with information on how to identify and access high-quality treatment."

-Kelly Clark, MD, MBA, DFASAM
Immediate-Past President of ASAM



Appropriate Use of Drug Testing in Clinical Addiction Medicine

Provides guidance about the effective use of drug testing in the identification, diagnosis, treatment and promotion of recovery for patients with, or at risk for, addiction.


The ASAM National Practice Guideline

The ASAM National Practice Guideline and associated resources provide information on evidence-based treatment of opioid use disorder.


Confidentiality (42 CFR Part 2)

Learn how ASAM continues to call for needed privacy protections as 42 CFR Part 2 regulations and the underlying statute are updated. 

Related News


Addiction Medicine Community Applauds Passage of House’s Bipartisan Legislative Package to Combat the Opioid Addiction & Overdose Epidemic

by ASAM Staff | Jun 22, 2018

Download PDF

Energy & Commerce Committee Summary of the SUPPORT Act

Energy & Commerce Committee Summary of the OPPS Act

KFF Brief on Medicaid Provisions in the SUPPORT ACT


Addiction Medicine Community Applauds Passage of House’s Bipartisan Legislative Package to Combat the Opioid Addiction & Overdose Epidemic
Bipartisan Legislative Package Lays Groundwork for Systemic Changes to America’s Addiction Prevention, Treatment, and Recovery Support Delivery Systems

Rockville, MD – The American Society of Addiction Medicine (ASAM) applauds the House of Representatives for its action this week to pass the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act (H.R. 6), the Overdose Prevention and Patient Safety (OPPS) Act (H.R. 6082), and the IMD Care Act (H.R. 5797). The sweeping legislative package makes important reforms on a range of issues including improving patient care coordination and safety, expanding the addiction treatment workforce, expanding access to addiction treatment, enhancing peer support specialist programs, ensuring the provision of evidence-based treatment, and improving provider education.

“As the leading voice of America’s addiction treatment professionals, ASAM commends the House for recognizing the magnitude and urgency of this public health crisis and taking steps to bolster our addiction treatment infrastructure,” said ASAM president Kelly J. Clark, MD, MBA, DFASAM. “The opioid addiction and overdose epidemic has ravaged our communities for too long, and we must continue to make actionable policy changes to stem the tide of overdoses and deaths. Many of the reforms made in the SUPPORT Act, OPPS Act, and IMD Care Act will help modernize our addiction treatment infrastructure and better integrate addiction treatment into mainstream medical care.”

The bipartisan legislation makes significant strides that will improve access to, and the quality of treatment for, persons suffering from addiction. The SUPPORT Act includes provisions that would:

  • Help ensure that programs funded by the Department of Health and Human Services (HHS), aiming to prevent or treat a mental health or substance use disorder (SUD), are evidence-based;
  • Grant more flexibility to the National Institutes of Health to conduct research to address the opioid addiction and overdose crisis;
  • Require state Children’s Health Insurance Programs (CHIP) to cover mental health benefits, including SUD services, for children and pregnant women;
  • Clarify telemedicine waivers;
  • Establish a federal loan repayment program that helps participants who pursue full-time substance use disorder treatment jobs in high-need geographic areas repay their student loans;
  • Require the HHS Secretary to convene a stakeholder group to report on best practices related to health care related transitions for inmates of public institutions;
  • Make permanent the authorization that allows qualifying nurse practitioners and qualifying physician assistants to treat patients with buprenorphine;
  • Permit qualifying practitioners to treat up to 100 patients at a time with buprenorphine (in lieu of the initial 30 patient limit) if the qualifying practitioner is board-certified in addiction medicine or addiction psychiatry or provides medication for addiction treatment in a qualified practice setting;
  • Permit qualifying certified registered nurse anesthetists, qualifying clinical nurse specialists, and qualifying certified nurse midwives to treat patients with buprenorphine for addiction involving opioid use for five years;
  • Expand Medicare coverage for certain services provided in opioid treatment programs; and
  • Require the HHS Secretary to conduct a four-year Medicare demonstration project to improve the treatment of addiction involving opioid use in office-based settings

The OPPS Act makes targeted revisions to the 42 CFR Part 2 confidentiality law to improve care coordination, while maintaining important confidentiality protections for patients with substance use disorder.

Finally, the IMD Care Act expands residential treatment for opioid use disorder and cocaine use disorder. The legislation would allow states to use Medicaid funds for up to 30 days of treatment per service year provided in an Institute of Mental Disease (IMD) for a period of 5 years. To do so, a state would have to submit a plan amendment to the Centers for Medicare & Medicaid Services (CMS) with information about how the state will improve access to outpatient care and detail a process by which an individual would transition from an IMD to appropriate outpatient care. States would also have to include a description of appropriate clinical screenings of eligible individuals – including assessments to determine appropriate level of care and length of stay – based upon the ASAM Criteria.

“While it is imperative that we increase access to treatment and addiction medicine specialists, it is also important that patients and families demand high-quality treatment based on clinical outcomes evidence and research,” said Dr. Clark.

In a letter last year to state Medicaid Directors, the Centers for Medicare and Medicaid (CMS) provided detailed Section 1115 demonstration guidance to states regarding strategies to address the opioid epidemic, including milestones related to treatment assessments based on substance use disorder (SUD)-specific, multi-dimensional assessment tools, such as the ASAM Criteria, as well as the use of nationally-recognized, evidence-based SUD program standards to set residential treatment provider qualifications.

“ASAM welcomes the bipartisan legislative achievements of the United States House of Representatives this week and looks forward to continuing our collaborative efforts with Congress and the Administration to expand access to high-quality, evidence-based addiction treatment for all Americans who need it,” Dr. Clark concluded.


About ASAM

The American Society of Addiction Medicine, founded in 1954, is a professional society representing over 5,300 physicians, clinicians, and associated professionals in the field of addiction medicine. ASAM is dedicated to increasing access and improving the quality of addiction treatment, educating physicians and the public, supporting research and prevention, and promoting the appropriate role of physicians in the care of patients with addiction. For more information, visit www.ASAM.org.